Clinical trials: Eye Infections, Bacterial
Bacterial Conjunctivitis
AL-15469A for the Treatment of Bacterial Conjunctivitis
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
- Trial name
- NCT00331916
- Testing
- quinolone
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Alcon Research
Ocular Inflammation, Infection Associated Blepharitis
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or…
- Conditions
- Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial
- Trial name
- NCT01721694
- Testing
- azithromycin 1.5% + Loteprednol 0,5% (separately)
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Trachoma
App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders
Trachomatous inflammation-follicular (TF) is diagnosed by looking for clinical signs of infection of everted eyelids (conjunctivae) of children.
- Trial name
- NCT04002726
- Testing
- Inter-grader agreement (IGA) app
- Where
- Tanzania
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cytomegalovirus Infections, Cytomegalovirus Retinitis
A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection
The purpose of this study is to understand how changes in the immune system of HIV-infected patients affect their risk for 3 serious infections: Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) retinitis, or CMV organ…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00005572
- Where
- 16 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Trachoma
Azithromycin in Control of Trachoma II
Trachoma is the world's leading cause of preventable blindness. This disease, caused by Chlamydia trachomatis, is endemic in many parts of the developing world.
- Trial name
- NCT00286026
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Corneal Ulcer, Eye Infections, Fungal
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
The purpose of this study is to determine if the addition of oral voriconazole to topical treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.
- Trial name
- MUTTII (NCT00997035)
- Testing
- Voriconazole
- Where
- 7 sites in United States, India and 1 more
- Volunteers
- 240 people
- Sponsor
- University of California, San Francisco
Child Development
Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
The use of antibiotics has saved millions of human lives, however consumption of antibiotics can select for antibiotic resistant organisms and may lead to changes in commensal microbiome.
- Trial name
- ARMCA (NCT03187834)
- Testing
- Azithromycin, Amoxicillin, Cotrimoxazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chlamydial Conjunctivitis
The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydia trachomatis is one of the major causes of sexually transmitted disease and also the leading infectious cause of blindness in the world.Treatment of C. trachomatis eye infection has involved for a long time.
- Trial name
- NCT01178762
- Testing
- Azithromycin
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- National Taiwan University Hospital
Increased Lordosis/Scoliosis, Hyporeflexia
Biomarker for Duchenne Muscular Dystrophy
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
- Conditions
- Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness
- Trial name
- BioDuchenne (NCT02994030)
- Where
- 12 sites in Albania, Egypt and 6 more
- Volunteers
- 103 people
- Sponsor
- CENTOGENE GmbH Rostock
Bacterial Conjunctivitis
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1%…
- Trial name
- NCT06911424
- Testing
- Fusidic Acid 1%
- Where
- 38 sites in United States
- Volunteers
- 400 people
- Sponsor
- Baxis Pharmaceuticals, Inc.
Conjunctivitis, Bacterial
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety
- Trial name
- NCT00357773
- Testing
- Azithromycin (T1225)
- Sponsor
- Laboratoires Thea
Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Fluorometholone Study
The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic…
- Trial name
- NCT07308938
- Testing
- Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Vishal Jhanji
Bacterial Conjunctivitis
Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
To assess safety and efficacy of AL-15469A 0.5% /AL-6515 0.3% Ophthalmic Suspension for treatment of bacterial conjunctivitis
- Trial name
- NCT01238783
- Testing
- AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension, AL-15469A 0.5%, AL-6515 0.3%
- Sponsor
- Alcon Research
Trachoma, Chlamydia
Tripartite International Research for the Elimination of Trachoma
Mass antimicrobial administrations have been remarkably successful in reducing the prevalence of the ocular strains of Chlamydia that cause trachoma.
- Trial name
- TIRET (NCT01202331)
- Testing
- mass treatment with oral azithromycin
- Where
- Ethiopia
- Volunteers
- 29,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trichiasis, Trachoma
Fluorometholone as Ancillary Therapy for TT Surgery
The investigators aim to evaluate a new potentially cost-effective approach to improving trichiasis surgery outcomes, perioperative topical anti-inflammatory therapy.
- Conditions
- Trichiasis, Trachoma, Bilamellar Tarsal Rotation
- Trial name
- NCT01949454
- Testing
- Fluorometholone 0.1% ophthalmic solution
- Where
- Ethiopia
- Volunteers
- 154 people
- Sponsor
- University of Pennsylvania
Bacterial Conjunctivitis
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive…
- Trial name
- NCT02432807
- Testing
- Vancomycin 1.1%
- Where
- 16 sites in United States
- Volunteers
- 303 people
- Sponsor
- Kurobe LLC
Infective Keratitis
Microbial Keratitis in Cairo University Hospitals
The aim of the study was to identify the incidence of infective keratitis presenting to the ophthalmology emergency department at Cairo University hospital, the risk factors and the bacterial/fungal spectrum causing the ulcers…
- Trial name
- NCT05387993
- Where
- Egypt
- Volunteers
- 85 people
- Sponsor
- Kasr El Aini Hospital
Trachoma, Chlamydia
Trachoma Elimination Follow-up
The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary.
- Trial name
- TEF (NCT00221364)
- Testing
- Mass treatment with oral azithromycin to an entire village
- Where
- Ethiopia
- Volunteers
- 20,000 people
- Sponsor
- University of California, San Francisco
Trachoma, Yaws
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF.
- Conditions
- Trachoma, Yaws, Lymphatic Filariases, Scabies
- Trial name
- NCT03676140
- Testing
- Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1
- Where
- Papua New Guinea
- Volunteers
- 20,000 people
- Sponsor
- Lihir Medical Centre
Infected Corneal Ulcers, Bacterial Keratitis
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons.
- Conditions
- Infected Corneal Ulcers, Bacterial Keratitis, Corneal Ulcer, Childhood Blindness
- Trial name
- NCT00386958
- Testing
- Povidone-Iodine
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center